CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Elderberry Juice +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02414607
NCT02414607Phase 2Completed

Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment

University of Missouri-Columbia·interventional·Posted Apr 13, 2015·Updated Jun 23, 2022

In Brief

A Phase 2 clinical trial evaluating Elderberry Juice and Placebo for Mild Cognitive Impairment. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Elderberries (Sambuci fructus) have been shown in a number of studies to have significant anti-inflammatory and antioxidant effects. Multiple human and animal studies have supported the anti-inflammatory and antioxidant effects of elderberry preparations and it has been used in natural medicine for hundreds of years. Studies examining factors that may decrease the risk of Alzheimer's disease have revealed that drinking juices with similar properties to elderberries is one of the most reliable way to decrease risk. As such the investigators wish to determine the effects of elderberry juice on cognitive decline in a group of subjects at high risk for Alzheimer's disease, those with mild cognitive impairment. Elderberry juice is a commercially available nutritional supplement and easily available to this population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 13, 2015
Enrollment StartSep 1, 2016
Primary CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.2 years ago

Interventions

Elderberry Juicebiological

Placeboother